# Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma

> **NCT04474353** · PHASE1 · COMPLETED · sponsor: **Stanford University** · enrollment: 12 (actual)

## Conditions studied

- Glioblastoma
- Newly Diagnosed Glioblastoma

## Interventions

- **DEVICE:** Optune
- **DRUG:** Gadolinium
- **DRUG:** Temozolomide
- **RADIATION:** Stereotactic radiosurgery (SRS)

## Key facts

- **NCT ID:** NCT04474353
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-21
- **Primary completion:** 2024-11-14
- **Final completion:** 2025-09-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474353, "Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04474353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*